After a year of layoffs and restructuring, Valeant Pharma scores big with a collaboration deal worth up to $670 million.

The industry is a-changing. Here are eight seminal events that describe how.

Tacked on to Genentech's press statement about its rejection of Roche's offer, the biotech firm announced the formation of a program to address employee concerns.

Whether or not BMS's $4.5 billion offer for ImClone is fair is up in the air, but either way BMS stands to gain chunk of change if its bid is approved.

After years of owning a majority share in Genentech, Roche makes a play to buy out the rest of the biotech firm.

Fresenius snagged injectible manufacturer APP Pharmaceuticals in a $3.7 billion cash deal. Along with entry into the US market, Fresenius also gets access to one of the largest suppliers of heparin.

In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys.

Small biotech company is creating a buzz with a diabetes drug that incorporates a component found in red wine. Pharm Exec talks to Sirtris CEO Christoph Westphal about the merger and the battle against diseases of aging.

Japanese drugmaker buys the cancer-specialist biotech for a whopping $8.8 billion.